Story perspectives

New Weight Loss Pills Show Promise Amid Safety Concerns

11/28/2025

Summary

Story summary

Eli Lilly and Company's Orforglipron shows 12.4% weight loss over 72 weeks, offering a daily alternative to injections like Ozempic and Mounjaro.
Novo Nordisk A/S is developing a similar pill using semaglutide, with 16.6% weight reduction; both drugs await FDA approval, with costs starting at $149 monthly.
Users of GLP-1 medications report digestive issues and a higher risk of chronic cough, underscoring the need for further safety and efficacy research.

1 of 1

Story summary

Eli Lilly and Company's Orforglipron shows 12.4% weight loss over 72 weeks, offering a daily alternative to injections like Ozempic and Mounjaro.
Novo Nordisk A/S is developing a similar pill using semaglutide, with 16.6% weight reduction; both drugs await FDA approval, with costs starting at $149 monthly.
Users of GLP-1 medications report digestive issues and a higher risk of chronic cough, underscoring the need for further safety and efficacy research.